You searched for clinical trials - Page 12 of 44

ASCO 2023: Dr. Jennifer Woyach on Combination Ibrutinib, Venetoclax, and Obinutuzumab for Previously Untreated CLL

September 15, 2023

In the setting of the COVID-19 pandemic, progression-free survival with first-line ibrutinib + venetoclax + obinutuzumab treatment was not superior to ibrutinib + obinutuzumab for older patients with previously untreated CLL. Follow-up remains ongoing, and many patients in the ibrutinib + venetoclax + obinutuzumab arm achieved undetectable measurable residual disease.

CLL Medicine Cabinet

August 31, 2023

Understanding the medication you are on, or those you and your healthcare provider are considering for your treatment plan is important in decision-making, managing expectations, and addressing concerns and side effects in order to maximize the benefits of therapy.

Treatment Outcomes for Patients with CLL and SLL Treated with First Line Ibrutinib Versus Chemoimmunotherapy

August 16, 2023

More research is presented again, proving that targeted therapies, in this case, ibrutinib, are significantly superior to chemoimmunotherapy (CIT) in front-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL).

BTK Inhibitors in Chronic Lymphocytic Leukemia

August 16, 2023

BTK is a good therapeutic target in CLL because it is only critical for the function of B-cells, and thus loss of BTK is not lethal for the patient.

ASH 2022: Time to Next Therapy with Acalabrutinib vs Ibrutinib

August 16, 2023

This real-world study found that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib were more likely to need to change therapies or add an additional therapy compared with patients treated with ibrutinib.

A Study of Frontline Therapy in Adults 80 Years and Older with Chronic Lymphocytic Leukemia (CLL)

August 16, 2023

In those over 80 with chronic lymphocytic leukemia (CLL), older age and not being treated with a novel agent frontline were associated with increased mortality. The leading cause of death in this group was the CLL itself.

Dr. Koffman’s Bispecific T-cell Engager Trial Blog

August 15, 2023

Dr. Koffman’s Bispecific T-cell Engager Trial Blog

My Personal Decision to Restart My CLL (Chronic Lymphocytic Leukemia) Treatment

August 15, 2023

Before deciding on the best therapy choice to treat my CLL / SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma), I first needed to determine if it was the right time to start therapy.

August 2023 CLL Bloodline

August 1, 2023

Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL. It will also provide news, help with the acronyms and new vocabulary words, and offer simple fun quizzes. The cycle restarts and it is updated annually.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: clinical trials – Page 12

ASCO 2023: Dr. Jennifer Woyach on Combination Ibrutinib, Venetoclax, and Obinutuzumab for Previously Untreated CLL

CLL Medicine Cabinet

Treatment Outcomes for Patients with CLL and SLL Treated with First Line Ibrutinib Versus Chemoimmunotherapy

BTK Inhibitors in Chronic Lymphocytic Leukemia

ASH 2022: Time to Next Therapy with Acalabrutinib vs Ibrutinib

A Study of Frontline Therapy in Adults 80 Years and Older with Chronic Lymphocytic Leukemia (CLL)

Dr. Koffman’s Bispecific T-cell Engager Trial Blog

My Personal Decision to Restart My CLL (Chronic Lymphocytic Leukemia) Treatment

August 2023 CLL Bloodline

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT